Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients.
Martínez-Fernandez A, García-Albeniz X, Pineda E, Visa L, Gallego R, Codony-Servat J, Augé JM, Longarón R, Gascón P, Lacy A, Castells A, Maurel J. Martínez-Fernandez A, et al. Among authors: gascon p. Ann Surg Oncol. 2009 May;16(5):1412-20. doi: 10.1245/s10434-009-0405-9. Epub 2009 Mar 4. Ann Surg Oncol. 2009. PMID: 19259740 Clinical Trial.
Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer.
Maurel J, Martin-Richard M, Conill C, Sánchez M, Petriz L, Ginès A, Miquel R, Gallego R, Cajal R, Ayuso C, Navarro S, Marmol M, Nadal C, Augé JM, Fernández-Cruz L, Gascón P. Maurel J, et al. Among authors: gascon p. Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1391-8. doi: 10.1016/j.ijrobp.2006.07.008. Epub 2006 Sep 11. Int J Radiat Oncol Biol Phys. 2006. PMID: 16965868 Clinical Trial.
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Gascón P, Castellví-Bel S, Maurel J. Garcia-Albeniz X, et al. Among authors: gascon p. Tumour Biol. 2011 Apr;32(2):417-24. doi: 10.1007/s13277-010-0136-3. Epub 2010 Nov 23. Tumour Biol. 2011. PMID: 21104178
[Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage].
Soriano-Izquierdo A, Adet AC, Gallego R, Miquel R, Castells A, Pellisé M, Nadal C, López-Boado MA, Piqué JM, Gascón P, Conill C, Bombí A, Fernández-Cruz L, Maurel J, Navarro S. Soriano-Izquierdo A, et al. Among authors: gascon p. Med Clin (Barc). 2009 Feb 14;132(5):163-71. doi: 10.1016/j.medcli.2008.07.012. Epub 2009 Feb 7. Med Clin (Barc). 2009. PMID: 19211081 Spanish.
Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results.
Reguart N, Viñolas N, Casas F, Gimferrer JM, Agustí C, Molina R, Martin-Richard M, Sanchez-Reyes A, Gascón P. Reguart N, et al. Among authors: gascon p. Lung Cancer. 2004 Jul;45(1):67-75. doi: 10.1016/j.lungcan.2003.12.012. Lung Cancer. 2004. PMID: 15196736 Clinical Trial.
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz A, Codony J, Gascon P, Mellado B. Domingo-Domenech J, et al. Among authors: gascon p. Ann Oncol. 2008 Feb;19(2):269-75. doi: 10.1093/annonc/mdm490. Epub 2007 Nov 12. Ann Oncol. 2008. PMID: 17998285 Free article.
316 results